Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
36.88
+2.57 (7.49%)
At close: Aug 13, 2025, 4:00 PM
37.04
+0.16 (0.43%)
After-hours: Aug 13, 2025, 6:24 PM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $66.77M in the quarter ending June 30, 2025, with 26,714.86% growth. This brings the company's revenue in the last twelve months to $85.74M, up 2,635.74% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$85.74M
Revenue Growth
+2,635.74%
P/S Ratio
51.00
Revenue / Employee
$172,165
Employees
498
Market Cap
4.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CYTK News
- 5 days ago - Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 19 days ago - Cytokinetics Merits A Speculative Buy Rating - Seeking Alpha
- 20 days ago - Cytokinetics to Announce Second Quarter Results On August 7, 2025 - GlobeNewsWire
- 26 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - GlobeNewsWire